CymaBay Therapeutics, Inc.
CBAY
Clasificación en acciones
#5847
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Precio por acción
$32.48
Última sincronización: 2024-03-25
Capitalización bursátil
$2.24B
Cambio (1 día)
0.00%
Cambio (1 año)
-0.01%
País
US
Comercio CymaBay Therapeutics, Inc. (CBAY)
Categoría
Healthcare
Capitalización de mercado de CymaBay Therapeutics, Inc.(CBAY)
Capitalización bursátil: $2.24B
A fecha de October 2026, CymaBay Therapeutics, Inc. tiene una capitalización de mercado de $2.24B. Esto convierte a CymaBay Therapeutics, Inc. en la 5847th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de CymaBay Therapeutics, Inc. desde 2018 hasta 2026
CBAY en comparación con los más populares 5 títulos stocks
